QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (20) Citing Articles via Google Scholar Google Scholar Articles by Frederick, L. Articles by James, C. D. Search for Related Content PubMed PubMed Citation

Analysis of genomic rearrangements associated with EGFRvIII expression suggests involvement of Alu repeat elements

Department of Laboratory Medicine and Pathology and Tumor Biology Program, Mayo Clinic and Foundation, Rochester, MN 55905

² Address correspondence and reprint requests to C. David James, Mayo Clinic, 200 First St., S.W., Hilton Bldg. Rm. 820-D, Rochester, MN 55905.

Abstract

We have developed a polymerase chain reaction (PCR)-based strategy for the synthesis and analysis of rearranged epidermal growth factor receptor (EGFR) fragments associated with the vIII mutant receptor expressed in glioblastomas with EGFR amplification. The sequencing of aberrant tumor fragments showed that intragenic deletion rearrangements consistently involve an approximately 600-bp region in intron 7 of EGFR and several rearrangement sites interspersed throughout the large (>100 kb) first intron of this gene. Examination of the intron 7 breakpoint region revealed an Alu repeat element, and all intron 7 rearrangement sites were located within or downstream of this repeat sequence. Analysis of intron 1 for similar sequences resulted in the identification of 11 sites containing >80% homology with parts of the Alu element in intron 7. Reverse transcriptase-PCR and/or Western analysis of the tumors showed the presence of EGFRvIII cDNAs and/or proteins, respectively, in all cases for which a rearranged genomic fragment was generated by long-range PCR. Collectively, these data suggest that EGFR rearrangements, associated with the synthesis of the most common EGFR mutant, are mediated by a specific sequence element.

This article has been cited by other articles:

				A. F. Gazdar and J. D. Minna Deregulated EGFR Signaling during Lung Cancer Progression: Mutations, Amplicons, and Autocrine Loops Cancer Prevention Research, August 1, 2008; 1(3): 156 - 160. [Full Text] [PDF]

				P. J. French, J. Peeters, S. Horsman, E. Duijm, I. Siccama, M. J. van den Bent, T. M. Luider, J. M. Kros, P. van der Spek, and P. A. Sillevis Smitt Identification of Differentially Regulated Splice Variants and Novel Exons in Glial Brain Tumors Using Exon Expression Arrays Cancer Res., June 15, 2007; 67(12): 5635 - 5642. [Abstract] [Full Text] [PDF]

				K.-K. Wong, Y. T.M. Tsang, Y.-M. Chang, J. Su, A. M. Di Francesco, D. Meco, R. Riccardi, L. Perlaky, R. C. Dauser, A. Adesina, et al. Genome-Wide Allelic Imbalance Analysis of Pediatric Gliomas by Single Nucleotide Polymorphic Allele Array Cancer Res., December 1, 2006; 66(23): 11172 - 11178. [Abstract] [Full Text] [PDF]

				H. Ji, X. Zhao, Y. Yuza, T. Shimamura, D. Li, A. Protopopov, B. L. Jung, K. McNamara, H. Xia, K. A. Glatt, et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors PNAS, May 16, 2006; 103(20): 7817 - 7822. [Abstract] [Full Text] [PDF]

				G. Choe, J. K. Park, L. Jouben-Steele, T. J. Kremen, L. M. Liau, H. V. Vinters, T. F. Cloughesy, and P. S. Mischel Active Matrix Metalloproteinase 9 Expression Is Associated with Primary Glioblastoma Subtype Clin. Cancer Res., September 1, 2002; 8(9): 2894 - 2901. [Abstract] [Full Text] [PDF]

				G. D. Eley, J. L. Reiter, A. Pandita, S. Park, R. B. Jenkins, N. J. Maihle, and C. D. James A chromosomal region 7p11.2 transcript map: Its development and application to the study of EGFR amplicons in glioblastoma Neuro-oncol, April 1, 2002; 4(2): 86 - 94. [Abstract] [PDF]